化学療法誘発性好中球減少症治療市場規模、シェア、動向分析レポート：治療別、医薬品別、投与経路別、流通経路別、地域別、セグメント別予測、2025年～2030年

化学療法誘発性好中球減少症（CIN）治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の化学療法誘発性好中球減少症治療市場は2030年までに15億1,000万米ドルに達すると予測され、2025～2030年のCAGRは-0.48％で減少すると予測されています。

この減少は、従来の化学療法に比べて化学療法誘発性好中球減少症の発生率を低下させる標的がん治療や免疫療法の採用拡大など、複数の要因によるものと考えられます。精密医療が進歩するにつれて、腫瘍医は骨髄抑制作用を最小限に抑える治療法へとますますシフトしており、それによってCIN治療の需要が減少しています。しかし、在宅医療や自己投与可能な治療法の台頭は、製薬企業にとって患者の利便性を向上させる使いやすい製剤を開発する機会にもなっています。

がん治療による重篤な副作用である化学療法誘発性好中球減少症は、化学療法を受ける患者に重大なリスクをもたらします。がん患者の有病率が上昇を続ける中、効果的なCIN治療に対する需要が医療セグメントの大幅な成長を牽引しています。開発企業は、治療法の進歩、新薬の開発、患者ケアソリューションの改善を活用して、この重大な症状に対処しています。市場は成長因子、抗生物質、抗真菌剤、その他の支持療法への投資の増加を目の当たりにしており、CINのより良い管理と関連合併症の減少を確実にしています。

CINと効果的に闘うために、成長因子は白血球産生を刺激し、罹患患者の感染症リスクを軽減するという重要な役割を担っています。顆粒球コロニー刺激因子（G-CSF）は主要な治療オプションであり、好中球の回復を促進し、化学療法の遅れを最小限に抑えます。Amgen Inc.、Sandoz、Teva Pharmaceutical Industries Ltd.、Coherus BioSciences、Viatris Inc.、Biocon Biologics Inc.などの主要製薬企業がG-CSF開発の最前線にいます。

フィルグラスチムは、好中球の回復を促進する遺伝子組換え型G-CSFとして広く使用されています。フィルグラスチムの長時間作用型であるペグフィルグラスチムは投与回数を減らし、リペグフィルグラスチムは持続的な好中球刺激を記載しています。エフラペグラスチムは新規の長時間作用型G-CSFで、CINに対する効果的な予防を提供し、エフベマレノグラスチムアルファは好中球支持を強化するために開発中の次世代治療です。さらに、顆粒球マクロファージコロニー刺激因子（GM-CSF）は好中球回復における治療の可能性を広げています。Pfizer Inc.、Spectrum Pharmaceuticals, Inc.、Evive Biotech、G1 Therapeutics, Inc.などの主要市場参入企業は、これらの治療効果を向上させるために研究開発に積極的に投資しています。

しかし、成長因子を使用してもCIN患者は細菌や真菌に感染しやすいため、予防的・治療的抗生物質の使用が極めて重要です。予防的抗生物質は高リスク患者の感染予防に重要な役割を果たし、治療的抗生物質は感染症が発症した場合に投与されます。同様に抗真菌薬も日和見感染症対策に役立ち、包括的な患者ケアを保証します。これらの治療法は総合的に、CINがもたらすリスクに対する多層防御システムを形成します。予防的抗生物質は好中球減少症患者の感染率を低下させる予防措置として機能し、一方、治療的抗生物質は免疫系の低下によって生じる細菌感染症に対処するのに役立ちます。また、抗真菌剤は、化学療法を受けている患者にとって生命を脅かす可能性のある侵襲性真菌感染症に対する防御を強化します。

これらの従来の治療選択肢に加えて、顆粒球輸血や免疫調節剤などの新たな治療法が、好中球減少症の重症例に対する潜在的な解決策として注目を集めています。継続的な研究と技術革新により、これらの治療法の有効性と利用しやすさが向上し、市場環境がさらに強化されることが期待されます。CIN治療市場は、ブランド薬とバイオシミラーに分けられます。ブランド医薬品はその確立された有効性により引き続き優位を占めているが、バイオシミラー医薬品はその費用対効果と採用の増加により急速に普及しています。規制当局の承認が拡大し、医療へのアクセスが向上するにつれて、バイオシミラーの選択肢がより広く利用できるようになり、より多くの患者が高価な先発医薬品の経済的負担を負うことなく、先進治療の恩恵を受けることができるようになっています。

新薬の開発とともに、ドラッグデリバリーの治療法も進化しています。非経口投与は依然としてCIN管理におけるゴールドスタンダードであり、G-CSFや抗生物質については、迅速かつ効果的な結果を得るために静脈内投与や皮下投与が推奨されています。しかし、予防的抗生物質や免疫調節剤の経口投与は、外来治療での利便性を高め、人気を集めています。このような投与方法の変化は、患者へのアクセスを向上させ、慢性的な治療管理における病院への依存を減らすという医療全体の動向と一致しています。

がんの負担が世界的に増加し続ける中、CIN治療市場は大幅に拡大する見込みです。バイオシミラーの採用の増加、薬剤開発の継続的な進歩、革新的な治療法の継続的な研究が、総体的にCIN管理の将来を形成しています。認知度の向上、治療プロトコルの改善、支持療法への投資の増加により、CIN治療の将来は大きな進展を確認することになると考えられます。これらの開発は、患者の予後を改善するだけでなく、世界の医療ソリューションの全体的な進歩にも寄与しています。

化学療法誘発性好中球減少症治療市場レポートハイライト

• 治療法別では、成長因子セグメントが2024年の市場を独占しました。このセグメントの優位性は、その有効性が実証されていること、がん治療プロトコールに広く採用されていること、バイオシミラーの継続的な進歩によるものです。
• バイオシミラー医薬品は、規制当局による承認の増加、費用対効果、医療プロバイダーによる採用の拡大により、2024年の医薬品タイプ別セグメントで市場をリードしました。
• 投与経路別では、非経口剤が2024年の市場を独占しました。注射剤、特に静脈内投与と皮下投与のG-CSFは、経口投与に比べ作用発現が早く、バイオアベイラビリティが高いため、依然として主要な投与方法となっています。
• 流通チャネル別では、病院での化学療法が多いことから、病院薬局が2024年に最大の市場シェアを占めました。病院薬局はCIN治療の主要な供給源であり、重要な薬剤の即時入手と投与を確実にします。
• 北米がCIN治療市場をリードしたのは、医療インフラが確立されていること、がんに対する意識が高いこと、先進的な治療選択肢があることなどが要因です。同地域は研究と技術革新に力を入れており、市場の成長をさらに後押ししています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 化学療法誘発性好中球減少症治療市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 価格分析

第4章 化学療法誘発性好中球減少症治療市場：治療ビジネス分析

• 治療市場シェア、2024年と2030年
• 治療セグメントダッシュボード
• 市場規模と予測と動向分析（治療別、2018～2030年）
• 成長因子
• 抗生物質
• 抗真菌剤
• その他

第5章 化学療法誘発性好中球減少症治療市場：医薬品ビジネス分析

• 医薬品市場シェア、2024年と2030年
• 医薬品セグメントダッシュボード
• 市場規模、予測、動向分析（医薬品別、2018～2030年）
• ブランド医薬品
• バイオシミラー

第6章 化学療法誘発性好中球減少症治療市場：投与経路ビジネス分析

• 投与経路市場シェア、2024年と2030年
• 投与経路セグメントダッシュボード
• 市場規模、予測、動向分析（投与経路別、2018～2030年）
• 非経口
• 経口

第7章 化学療法誘発性好中球減少症治療市場：流通チャネル事業分析

• 流通チャネル市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 化学療法誘発性好中球減少症治療市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Amgen Inc.
  • Sandoz
  • Teva Pharmaceutical Industries Ltd
  • Coherus BioSciences Inc.
  • Coherus BioSciences Inc.
  • Viatris Inc.
  • Biocon Biologics Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Evive BIoTech
  • G1 Therapeutics, Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 5 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 6 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 7 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 10 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 11 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 12 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 14 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 15 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 16 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 18 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 19 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 20 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 21 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 22 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 23 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 24 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
• Table 26 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 27 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 28 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 29 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 31 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 32 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 33 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 35 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 36 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 37 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 38 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 39 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 40 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 41 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 43 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 44 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 45 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 48 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 49 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 50 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 52 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 53 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 54 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 56 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 57 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 58 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 60 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 61 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 62 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 67 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 69 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 70 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 71 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 73 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 74 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 75 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 77 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 78 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 79 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 80 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 81 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 82 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 83 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 85 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 86 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 87 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 89 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 90 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 91 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
• Table 93 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 94 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 95 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 96 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 97 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 98 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 99 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 100 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 101 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 102 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 103 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 104 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 109 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 110 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 111 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 112 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 113 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 116 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 117 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 118 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 119 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 120 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 121 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 122 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 123 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 124 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 125 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Chemotherapy-induced neutropenia (CIN) treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Treatment and Drug snapshot
• Fig. 11 Route of administration and distribution channel snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Parent market value, 2024 (USD billion)
• Fig. 14 Market dynamics
• Fig. 15 Porter's five forces analysis
• Fig. 16 PESTLE analysis
• Fig. 17 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment outlook and key takeaways
• Fig. 18 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment movement analysis
• Fig. 19 Growth factors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Antifungal agents market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Other treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Chemotherapy-induced neutropenia (CIN) treatment market: Drug outlook and key takeaways
• Fig. 24 Chemotherapy-induced neutropenia (CIN) treatment market: Drug movement analysis
• Fig. 25 Branded drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration outlook and key takeaways
• Fig. 28 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration movement analysis
• Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market outlook and key takeaways
• Fig. 32 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market movement analysis
• Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Chemotherapy-induced neutropenia (CIN) treatment market revenue, by region, 2024 & 2030 (USD Million)
• Fig. 37 Regional marketplace: Key takeaways
• Fig. 38 North America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Key country dynamics
• Fig. 40 U.S. chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Cancer incidence, 2022 - 2045
• Fig. 42 U.S. healthcare system: money flow
• Fig. 43 Key country dynamics
• Fig. 44 Canada chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Cancer incidence, 2022 - 2045
• Fig. 46 Key country dynamics
• Fig. 47 Mexico chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Cancer incidence, 2022 - 2045
• Fig. 49 Regulatory framework
• Fig. 50 Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Key country dynamics
• Fig. 52 UK chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Cancer incidence, 2022 - 2045
• Fig. 54 Key country dynamics
• Fig. 55 Germany chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Cancer incidence, 2022 - 2045
• Fig. 57 Exclusivity formula
• Fig. 58 Germany insurance coverage
• Fig. 59 Key country dynamics
• Fig. 60 France chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Cancer incidence, 2022 - 2045
• Fig. 62 Key country dynamics
• Fig. 63 Italy chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Cancer incidence, 2022 - 2045
• Fig. 65 Key country dynamics
• Fig. 66 Spain chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Cancer incidence, 2022 - 2045
• Fig. 68 Key country dynamics
• Fig. 69 Denmark chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Cancer Incidence, 2022 - 2045
• Fig. 71 Key country dynamics
• Fig. 72 Sweden chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Cancer incidence 2022 - 2045
• Fig. 74 Key country dynamics
• Fig. 75 Norway chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Cancer incidence, 2022 - 2045
• Fig. 77 Rest of Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Japan chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Cancer incidence, 2022 - 2045
• Fig. 82 Japan pharmaceutical registration
• Fig. 83 Key country dynamics
• Fig. 84 China chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 85 Cancer incidence, 2022 - 2045
• Fig. 86 Regulatory details: China
• Fig. 87 Key country dynamics
• Fig. 88 India chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 89 Cancer incidence, 2018 - 2030
• Fig. 90 Key country dynamics
• Fig. 91 Australia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 92 Cancer incidence, 2018 - 2030
• Fig. 93 Key country dynamics
• Fig. 94 Thailand chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 95 Cancer incidence, 2018 - 2030
• Fig. 96 Key country dynamics
• Fig. 97 South Korea chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 98 Cancer incidence, 2018 - 2030
• Fig. 99 Rest of Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 100 Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Key country dynamics
• Fig. 102 Brazil chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Cancer incidence, 2018 - 2030
• Fig. 104 Key country dynamics
• Fig. 105 Argentina chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Cancer incidence, 2018 - 2030
• Fig. 107 Rest of Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 108 MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Key country dynamics
• Fig. 110 South Africa chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 111 Cancer incidence, 2018 - 2030
• Fig. 112 Key country dynamics
• Fig. 113 Saudi Arabia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 114 Cancer incidence, 2018 - 2030
• Fig. 115 Key country dynamics
• Fig. 116 UAE chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 117 Cancer incidence, 2018 - 2030
• Fig. 118 Key country dynamics
• Fig. 119 Kuwait chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 120 Cancer incidence, 2018 - 2030
• Fig. 121 Rest of MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 122 Company/competition categorization
• Fig. 123 Strategy mapping

Chemotherapy-induced Neutropenia Treatment Market Growth & Trends:

The global chemotherapy-induced neutropenia treatment market is anticipated to reach USD 1.51 billion by 2030 and is expected to decline at a CAGR of -0.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. This decline can be attributed to multiple factors, including the growing adoption of targeted cancer therapies and immunotherapies, which reduce the incidence of chemotherapy-induced neutropenia (CIN) compared to traditional chemotherapy. As precision medicine advances, oncologists are increasingly shifting towards treatment modalities that minimize myelosuppressive effects, thereby reducing the demand for CIN treatments. However, the rise of home healthcare and self-administrable therapies also presents an opportunity for pharmaceutical companies to develop user-friendly formulations that improve patient convenience.

Chemotherapy-Induced Neutropenia (CIN), a severe side effect of cancer treatment, poses significant risks for patients undergoing chemotherapy. As the prevalence of cancer cases continues to rise, the demand for effective CIN treatments is driving substantial growth in the healthcare sector. Businesses are capitalizing on advancements in treatment modalities, novel drug developments, and improved patient care solutions to address this critical condition. The market is witnessing increased investments in growth factors, antibiotics, antifungal agents, and other supportive therapies, ensuring better management of CIN and reducing associated complications.

To combat CIN effectively, growth factors play a vital role in stimulating white blood cell production, reducing the risk of infections in affected patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are the primary treatment option, enhancing neutrophil recovery and minimizing chemotherapy delays. Leading pharmaceutical companies such as Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Viatris Inc., and Biocon Biologics Inc. are at the forefront of G-CSF development.

Filgrastim is a widely used recombinant G-CSF that accelerates neutrophil recovery. Pegfilgrastim, a longer-acting version of Filgrastim, reduces the frequency of administration, while Lipegfilgrastim offers sustained neutrophil stimulation. Eflapegrastim is a novel, long-acting G-CSF providing effective prophylaxis against CIN, and Efbemalenograstim alfa is a next-generation therapy under development for enhanced neutrophil support. Additionally, Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs) are expanding the therapeutic potential in neutrophil recovery. Key market players, including Pfizer Inc., Spectrum Pharmaceuticals, Inc., Evive Biotech, and G1 Therapeutics, Inc., are actively investing in research and development to improve the efficacy of these treatments.

However, even with the use of growth factors, CIN patients remain highly susceptible to bacterial and fungal infections, making the use of prophylactic and therapeutic antibiotics crucial. Prophylactic antibiotics play a key role in preventing infections in high-risk patients, while therapeutic antibiotics are administered when infections develop. Similarly, antifungal agents help combat opportunistic infections, ensuring comprehensive patient care. These treatments collectively form a multi-layered defense system against the risks posed by CIN. Prophylactic antibiotics serve as a preventive measure to reduce infection rates in neutropenic patients, whereas therapeutic antibiotics help manage bacterial infections that arise due to the weakened immune system. Meanwhile, antifungal agents provide an added layer of protection against invasive fungal infections, which can be life-threatening for patients undergoing chemotherapy.

In addition to these conventional treatment options, emerging therapies such as granulocyte transfusions and immunomodulatory agents are gaining attention as potential solutions for severe cases of neutropenia. Ongoing research and innovation are expected to enhance the effectiveness and accessibility of these treatment options, further strengthening the market landscape. The CIN treatment market is divided into branded drugs and biosimilars. Branded drugs continue to dominate due to their established efficacy, but biosimilars are rapidly gaining traction due to their cost-effectiveness and increasing adoption. As regulatory approvals expand and healthcare accessibility improves, biosimilar options are becoming more widely available, allowing more patients to benefit from advanced therapies without the financial burden of high-priced branded drugs.

Along with the development of new drug options, treatment delivery methods are also evolving. Parenteral administration remains the gold standard for CIN management, with intravenous (IV) and subcutaneous (SC) routes being preferred for G-CSFs and antibiotics to ensure rapid and effective results. However, oral options for prophylactic antibiotics and immunomodulatory agents are gaining popularity, offering greater convenience for outpatient care. This shift in administration methods aligns with the broader healthcare trend of enhancing patient accessibility and reducing hospital dependency for chronic care management.

As the burden of cancer continues to grow worldwide, the CIN treatment market is poised for substantial expansion. The increasing adoption of biosimilars, continuous advancements in drug development, and ongoing research into innovative therapies are collectively shaping the future of CIN management. With enhanced awareness, improved treatment protocols, and growing investment in supportive care, the future of CIN treatment is set to witness significant progress. These developments not only ensure better patient outcomes but also contribute to the overall advancement of global healthcare solutions.

Chemotherapy-induced Neutropenia Treatment Market Report Highlights:

• On the basis of treatment, the growth factors segment dominated the market in 2024. The segment's dominance is attributable to its proven efficacy, widespread adoption in cancer treatment protocols, and continuous advancements in biosimilars.
• Biosimilars led the drug type segment in market in 2024, driven by increasing regulatory approvals, cost-effectiveness, and growing adoption by healthcare providers..
• On the basis of the route of administration, the parenteral segment dominated the market in 2024. Injectable formulations, particularly intravenous and subcutaneous G-CSFs, remain the primary mode of administration due to the rapid onset of their action and higher bioavailability compared to oral alternatives.
• On the basis of distribution channel, the hospital pharmacies segment held the largest market share in 2024, driven by the high volume of chemotherapy conducted in hospital settings. Hospital pharmacies are the primary source of CIN treatment drugs, ensuring immediate availability and administration of critical medications
• North America led the CIN treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of cancer, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Drug
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Distribution Channel & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
    • 3.3.3.1. Phase 1
    • 3.3.3.2. Phase 2
    • 3.3.3.3. Phase 3
  • 3.3.4. Pricing Analysis

Chapter 4. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Growth Factors
  • 4.4.1. Growth Factors Market, 2018 - 2030 (USD Million)
• 4.5. Antibiotics
  • 4.5.1. Antibiotics Market, 2018 - 2030 (USD Million)
• 4.6. Antifungal Agents
  • 4.6.1. Antifungal Agents Market, 2018 - 2030 (USD Million)
• 4.7. Other Treatments
  • 4.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 5. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Drug Business Analysis

• 5.1. Drug Market Share, 2024 & 2030
• 5.2. Drug Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
• 5.4. Branded Drugs
  • 5.4.1. Branded Drugs Market, 2018 - 2030 (USD Million)
• 5.5. Biosimilars
  • 5.5.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 6. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Amgen Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Sandoz
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Teva Pharmaceutical Industries Ltd
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Coherus BioSciences Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Coherus BioSciences Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Viatris Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Biocon Biologics Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Pfizer Inc.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Spectrum Pharmaceuticals, Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Evive Biotech
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. G1 Therapeutics, Inc.
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives